Wednesday 3rd December, 2014
8:30am to 12:30pm
Following from its successful conference series, SMi Group are proud to introduce its masterclass taking place on 3rd December 2014 in Central London, ADC Development.
ADC Development will be hosted by PhotoBiotics Ltd, a multidisciplinary company spun out from Imperial College London. The PhotoBiotics RandD team has already succeeded in its initial objective of targeting photosensitiser-based drugs to tumours, generating compelling efficacy data in various orthotopic and xenograft models, and has a product ready to enter preclinical toxicology clinical development.
ADC Development will survey the state of the art in ADC technology giving an insight into which new approaches may lead to novel drug candidates with unique features and benefits. The bulk of the masterclass will comprise technical guidance on how to make drugs ready for bioconjugation, antibody drug conjugation strategies with some basic analytical tools. There will be plenty of time for interactive discussion and dissemination of best practice.
Mahendra Deonarain, Chief Science Officer
Gokhan Yahioglu, Co founder and Director of Chemistry
Ioanna Stamati, Team Leader
Why You Need to Attend:
ADCs now make up a significant proportion of the biopharma drug pipeline and multiple drug linker antibody format platforms are being investigated as the future generation of ADCs. It is important to keep up to date with latest conceptual and technical developments and also how to put some of these ideas into practice to discover and develop successful ADCs for oncology.
Please note that availability is based on first come first serve and is strictly limited.
Standard Rate: GBP 599+VAT
Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Drug Development
Sign in to add slides, notes or videos to this session